Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (4583)	2/10/2006 10:04:44 AM
From: sjemmeri	Read Replies (1) \| Respond to of 4974

Interesting that the IPO market has remained so weak for biotechs even though biotechs have had an extended good run in the market. Maybe the ones trying to IPO are obvious garbage? 2/9/2006 ACOR Drug developer Acorda Therapeutics cuts range -46% Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, sliced its range -46% to $6 to $7 from $11 to $13. The offering size remains the same at 5.5 million shares. Banc of America is the lead underwriter on the deal. The deal could price tonight and begin trading on the NASDAQ tomorrow under the symbol "ACOR."